SCHEDULE: Avoro Capital Advisors Discloses Stake in Soleno Therapeutics

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 4.45% of Soleno Therapeutics Inc. common stock as of March 31, 2026.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of Soleno Therapeutics Inc. common stock.
• As of March 31, 2026, the Reporting Persons collectively beneficially owned 2,300,000 shares of Soleno Therapeutics Inc. common stock.
• This ownership represents 4.45% of the class of securities.
• The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• Avoro Capital Advisors LLC is a Delaware limited liability company providing investment advisory and management services.
• Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC.
• The filing states that this should not be construed as an admission of beneficial ownership for purposes of Section 13 of the Act.
• The total number of outstanding shares of common stock used for the percentage calculation was 51,718,149 as of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the investment by a known firm is positive, the passive nature of the Schedule 13G and the disclaimer regarding beneficial ownership limit its immediate impact or insight into the company's performance.

Positives

• Significant investment by Avoro Capital Advisors LLC, a known investment firm, suggests confidence in Soleno Therapeutics' potential.
• The ownership stake of 4.45% indicates a notable position in the company.

Negatives

• The filing is a Schedule 13G, which is an informational filing for passive investors, and does not indicate any active role or intention to influence control.
• The statement explicitly notes that the filing should not be construed as an admission of beneficial ownership for purposes of Section 13 of the Act, potentially indicating a nuanced or limited beneficial ownership claim.

Risks

• The primary risk for investors is the passive nature of the filing, which does not provide insights into the company's operational performance or future prospects beyond the investment interest of Avoro Capital Advisors.
• As a Schedule 13G filing, it does not detail specific strategic plans or financial performance of Soleno Therapeutics, leaving investors to seek that information elsewhere.

Future Outlook

This filing is a Schedule 13G, which reports passive ownership and does not contain forward-looking statements or guidance from Soleno Therapeutics Inc. The future outlook for the company would need to be assessed from other filings or company communications.

Management Comments

• The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors taking significant, but passive, stakes in public companies. The presence of Avoro Capital Advisors LLC, an investment advisory firm, suggests a potential validation of Soleno Therapeutics' market position or future prospects from a sophisticated investor.

Stakeholder Impact

• Shareholders: The filing indicates a significant passive investment by an institutional investor, which may be viewed positively as a sign of confidence, but does not directly impact current operations or shareholder rights.
• Management: The filing does not directly involve management actions but reflects external investor interest.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Investors should consult other Soleno Therapeutics Inc. filings (e.g., 10-Q, 10-K) for operational and financial performance updates.
• Monitor future filings from Avoro Capital Advisors LLC for any changes in their stake or investment strategy regarding Soleno Therapeutics Inc.

Key Dates

Keywords

Soleno Therapeutics, Schedule 13G, Avoro Capital Advisors LLC, Behzad Aghazadeh, Beneficial Ownership, Investment, SEC Filing, Common Stock, Securities